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Electromagnetic-guided MLC Tracking Radiotherapy for Prostate Cancer 
Patients: Prospective Clinical Trial Results 
 
 
Abstract 
 
Purpose: To report on the primary and secondary outcomes of the prospective clinical trial of 
electromagnetic-guided MLC tracking radiotherapy for prostate cancer.   
 
Method and Materials: Twenty-eight men with prostate cancer were treated with electromagnetic-
guided MLC tracking with VMAT. 858 fractions were delivered with the dose per fraction ranging 
from 2 Gy to 13.75 Gy.  The primary outcome was feasibility with success determined if >95% of 
fractions were successfully delivered.  The secondary outcomes were (1) the improvement in beam-
target geometric alignment, (2) the improvement in dosimetric coverage of the prostate and avoidance 
of critical structures and (3) no acute grade ≥3 genitourinary or gastrointestinal toxicity.   
 
Results: All 858 planned fractions were successfully delivered with MLC tracking, demonstrating the 
primary outcome of feasibility (p<0.001). MLC tracking improved the beam-target geometric 
alignment from 1.4 mm to 0.90 mm (root mean square error). MLC tracking improved the dosimetric 
coverage of the prostate and reduced the daily variation in dose to critical structures.  No acute grade 
≥3 genitourinary or gastrointestinal toxicity was observed.  
 
Conclusions: Electromagnetic-guided MLC tracking radiotherapy for prostate cancer is feasible. The 
patients received improved geometric targeting and delivered dose distributions that were closer to 
those planned than they would have received without electromagnetic-guided MLC tracking.  No 
significant acute toxicity was observed.  
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Introduction 
Real-time prostate monitoring during radiotherapy was pioneered via the x-ray based Hokkaido real-
time radiotherapy system [1]. Since then, a number of technologies have been developed for real-time 
prostate monitoring. These technologies include a variety of other x-ray systems, ultrasound [2], MRI 
[3], and electromagnetic-based [4] monitoring systems. This study used the most widely-available 
electromagnetic monitoring system, the Calypso system (Varian Medical Systems, Palo Alto, CA, 
USA) [4].   
 
Intrafraction adaptation based on real-time prostate monitoring can occur via robotic or gimbaled 
shifting of the linac, adjusting the multileaf collimator (MLC), or adjusting the treatment couch.  The 
method used in this study is MLC tracking which has been experimentally implemented on Varian 
[5,6], Siemens [7] and Elekta [8,9] linear accelerators. The integration of electromagnetic monitoring 
with MLC tracking was first reported in 2009 [10,11], and the first patient treatment commenced in 
2013 [12].  
 
The clinical motivation for integrating electromagnetic monitoring with MLC tracking is to increase 
treatment accuracy, increasing the fidelity of the planned and delivered treatments, and ultimately to 
improve treatment outcomes.  Electromagnetic monitoring with gating for prostate cancer has 
demonstrated lower toxicity in a matched-pair analysis [13] and dosimetric improvements have been 
shown [14,15].  Electromagnetic monitoring with MLC tracking has also shown dosimetric benefits 
[15,16].  The advantages of MLC tracking over gating are threefold: (1) beam-target misalignments 
are always corrected with MLC tracking; these are only corrected if a threshold is exceeded with 
gating; (2) MLC tracking treatments can be initiated even if the target is outside what would be a 
threshold for gating, for example if the prostate position is 5 mm from the planned position, treatment 
can start as the beam corrects the offset position rather than needing to shift the patient; and (3) MLC 
tracking is more efficient as the corrections are integrated into the treatment; with gating the treatment 
needs to be paused to allow the automated or manual couch correction.  
 
The goal of this study to investigate the primary outcome of feasibility and the secondary outcomes of 
beam-target geometric alignment; dosimetric coverage of prostate and critical structures and acute 
genitourinary and gastrointestinal toxicity in the first prospective clinical trial of electromagnetic-
guided MLC tracking radiotherapy for prostate cancer.   
 
Method and Materials 
 
Study design and patients 
Twenty-eight men with prostate cancer were enrolled into a prospective electromagnetic-guided MLC 
tracking trial (NCT02033343) between November 2013 and July 2015. The eligibility criteria 
included: histologically proven prostate adenocarcinoma; prostate specific antigen (PSA) obtained 
within 3 months prior to enrolment; ability to have Calypso beacons implanted and body habitus 
enabling Calypso tracking (beacon-to-external-monitoring-array distance <19 cm); ECOG 
performance status 0-2 and informed consent. Patients were allowed to have a hydrogel spacer 
(SpaceOAR, Augmenix) at their discretion.  
 
All patients were treated with electromagnetic -guided MLC tracking with 6 MV VMAT. Two arcs 
were typically used, with three arcs used for two patients.  The clinical target volume (CTV) to 
planning target volume (PTV) margin for the stereotactic body radiotherapy (SBRT) regimens was 
5 mm in all directions except posteriorly where a 3 mm margin was used. The conventionally 
fractionated patients had a margin of 7 mm in all directions except posteriorly where a 5 mm margin 
was used. Two changes were made to allow for MLC tracking: (1) the collimator jaws were opened a 
further 8 mm to allow the real-time movement of the MLC aperture without moving beneath the 
collimator jaws and (2) if the jaws’ positions exceeded the 14.5cm leaf travel distance limit the 
collimator angle was adjusted. The patient characteristics and prescription doses are given in Table 1. 
Twenty-three of the 28 patients had additional MRI-defined gross tumor volume (GTV) escalation 
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which is relevant for high precision radiotherapy, such as that performed here, as the small boost 
volumes are more sensitive to motion errors. Per institutional protocol, no margin was added for the 
GTVs. It is acknowledged that there may be some geometric error between the motion of the 
electromagnetic beacons and the motion of the GTVs.   
 
The MLC tracking was enabled via an electromagnetic guidance position signal using a version of 
Calypso modified for research only use.  The position signal was sent to an in-house developed MLC 
tracking program [17] integrated with the Millennium 120-leaf MLC on a Varian Trilogy linear 
accelerator.  MLC-tracking specific quality assurance followed the Failure Mode and Effects Analysis 
(FMEA) of Sawant et al. [18]. The time delay between the target motion and the MLC tracking 
response was measured to be 230 ± 20 ms [12]. No prediction algorithm was used to account for this 
time delay due to the unpredictable motion of the prostate.  
 
Analysis details 
The primary outcome was feasibility with success determined if >95% of fractions were successfully 
delivered.  A fraction was deemed to have been successfully delivered if there was no equipment 
failure and the MLC tracked the beacons throughout the delivery of the treatment. The feasibility 
hypothesis was tested by calculating the probability of obtaining the observed number of successes, 
given a success rate of 0.95, using the Binomial test and a significance threshold of α=0.05. Statistical 
analysis was performed with Matlab (Mathworks, version 2017a) and R (www.r-project.org version 
3.4.0).   
 
Three secondary outcomes were (1) the improvement in beam-target geometric alignment, (2) the 
improvement in dosimetric coverage of prostate and avoidance of critical structures and (3) no acute 
grade ≥3 genitourinary or gastrointestinal toxicity.  The primary and secondary outcome measures are 
shown schematically in Figure 1. 
 
The effects of MLC-tracking on beam-target alignment were investigated by determining the 
geometric alignment of the beam center and target (transponder centroid) with MLC-tracking, and 
estimating the geometric alignment of the planned beam center and target i.e. without tracking. The 
planned beam-target alignment in beam’s eye view was the planned static target position  
relative to the planned beam center 		, i.e.  − 		. The beam-target 
geometric alignment with tracking, , was determined as the difference between the beam-
target alignment with tracking and the planned beam-target alignment:  
 
 =	  − 		 −  − 		. 
 
The beam-target geometric alignment without tracking, 	, can be expressed similarly, 
replacing the center of mass of the tracking beam with that from the plan:  
 
	 =	  − 		 −  − 		 =  − . 
 
For the geometric analysis, 803 of the 858 delivered fractions were included, with each fraction 
further separated into individual arcs.  The 55 excluded fractions were due to missing/corrupted data 
(accelerator faults, Calypso faults or data transfer issues).  No data was excluded due to an MLC 
tracking error. 
 
The assessment of the dosimetric coverage of the prostate and critical structures in the presence of 
motion used the dose reconstruction method of Poulsen [19]. This provided a comparison of 
dosimetric coverage of the prostate and critical structures, with and without MLC tracking.  An 
acknowledged limitation is that no deformation of the prostate or normal tissue is included. 787 of the 
858 fractions were included. Of the 71 excluded fractions, 44 were due to missing/corrupted data. 27 
fractions from 2 patients were excluded because they were treated with an isocenter off set. 490 of the 
787 fractions had GTV dose escalation.  
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The acute genitourinary and gastrointestinal toxicities were assessed by the treating physician using 
the Modified Radiation Therapy Oncology Group (RTOG) Toxicity Scale [20]. Follow up evaluations 
after radiotherapy were performed at intervals of 3 months and 12 months.  
 
Note that the data for the additional secondary outcomes planned for the trial of late toxicity and 
biochemical control will take at least five years to mature and are not reported here.   
 
Results 
Primary outcome: Feasibility 
For the primary feasibility outcome, all 858 of 858 attempted fractions of electromagnetic -guided 
MLC tracking were successful delivered to the 28 patients.  This yields a maximum likelihood 
estimated success rate of 100% with 1st and 99th percentile confidence limits of 99.5%-100%. 
Therefore, we accept the hypothesis that MLC tracking is feasible, i.e. successful for >95% of 
treatment fractions (p<0.001).   
 
Secondary outcome 1: The improvement in beam-target geometric alignment 
The improvement in beam-target geometric alignment is shown in Figure 2 for the VMAT arcs with 
the largest geometric error with and without MLC tracking. The maximum mean error with tracking 
was less than 1 mm. Without tracking the maximum mean error would have been over 6 mm.  
 
For the summary statistics compiled over all arcs, fractions and patients (Figure 2), the beam-target 
geometric alignment with MLC tracking was 0.90 mm (root-mean-square error). Without tracking the 
geometric alignment would have been 1.4 mm. The geometric alignment parallel to the beam 
direction has 1st and 99th percentiles of (-0.8 mm, 0.9 mm). Without tracking the alignment would 
have been (-3.6 mm, 3.1 mm). The geometric alignment perpendicular to the beam direction has 1st 
and 99th percentiles of (-2.4 mm, 2.3 mm). Without tracking the alignment would have been (-2.9 mm, 
3.6 mm). 
 
Secondary outcome 2: The improvement in dosimetric coverage of prostate and critical structures 
Isodose curves for the treatment fractions with the largest geometric beam-target alignment errors 
with and without tracking are shown in Figure 3. Summary dose statistics of the 787 fractions 
included in the dosimetric coverage analysis are given in Figure 4. An error in dosimetric coverage 
was defined as a greater than 5% difference in the planned and delivered doses to a volume or 
structure [21]. For the CTV, no errors were observed in the fractions with MLC tracking and 3 
fractions had errors without tracking. For the GTV, one fraction had errors with tracking and five 
fractions had errors without tracking. For the bladder V50%, 113 and 254 errors were observed with 
and without tracking respectively. For the rectum V50%, 228 and 502 errors were observed with and 
without tracking respectively. Note for the rectum and bladder that dose increases and decreases from 
the plan were observed, depending on the direction of prostate motion. 
 
Secondary outcome 3: The incidence of acute grade ≥3 genitourinary or gastrointestinal toxicity.   
There was no acute grade ≥3 genitourinary or gastrointestinal toxicity recorded from the trial.  Figure 
5 shows the 0 month (after treatment starts), 3 month and 12-month follow up toxicities. At 12 months 
there was one grade 2 genitourinary score and one grade 2 gastrointestinal score which was 
consistent. The patient with the 12-month grade 2 genitourinary toxicity was treated with 2 Gy × 
40 fractions and had a bladder dose at the higher end of allowable constraints.  The urethra was not 
contoured. The patient with the 12-month grade 2 gastrointestinal toxicity was treated with 12.5 Gy × 
2 fractions followed by 2 Gy × 23 fractions. There was no hydrogel and the rectal dose was at the 
higher end of allowable constraints.   
 
Discussion 
In this prospective trial, electromagnetic-guided MLC tracking radiotherapy for prostate cancer was 
successfully implemented for 858 treatment fractions for 28 prostate cancer patients with fractional 
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doses ranging from 2-13.75 Gy. The technology was proven to be feasible for >95% of prostate 
fractions. This feasibility is higher than may be expected when using vendor-supplied research 
interfaces to the electromagnetic tracking system and MLC and in-house developed MLC adaptation 
software. Though substantial testing and quality assurance processes were followed, these 
experimental technologies had not gone through the rigorous testing that would be required for 
clinically released products and regulatory approval.  This feasibility indicates that should 
electromagnetic-guided MLC tracking become available through a vendor, it has a high likelihood of 
successfully being deployed.   
 
As SBRT becomes more common, infrequent but significant motion of the prostate will have a greater 
impact on cancer control. SBRT to date has used smaller margins than conventional prostate 
radiotherapy, generally no greater than 5 mm, and commonly 3 mm. It has also been predominantly in 
low and intermediate risk patients with low volumes of significant cancers. Motion will be of greater 
importance when fewer fractions are used, but also when higher risk patients are treated. If a patient 
has a prostate completely infiltrated by high grade cancer then any motion greater than the PTV 
margin will move significant cancer outside the high dose field. In these scenarios, real time tracking 
is an ideal modality to guarantee full dose to the gross disease. It could be argued that in high risk 
patients undergoing stereotactic monotherapy it may be essential. Alternatives such as gating are 
viable, but can result in the beam starting and stopping frequently in some patients. Real time tracking 
should also have a small but real dosimetric improvement compared with gating. Other patients likely 
to benefit from tracking are those with a dominant intraprostatic lesion boost. In this scenario, doses 
upwards of 90 Gy are planned as a synchronous boost within the prostate, and are commonly planned 
with minimal or no margin for motion. Motion between 1-2 mm, which can not easily be adjusted for 
with gating, will therefore be significant. In this feasibility study, the margins – always a contentious 
issue – were not changed from standard practice and until the technology becomes more widespread 
or the clinical results mature we would recommend caution when changing margins. Electromagnetic-
guided MLC tracking will still suffer from interobserver target delineation variation and prostate 
deformation. 
 
The toxicity observed in the conventionally fractionated dose-escalated patients in this study was 
similar to that observed in a similar cohort of dose-escalated prostate cancer patients without MLC 
tracking [22]. As the margins and dose were similar between the two cohorts this implies MLC 
tracking is unlikely to increase side effects by negating the averaging of rectal and genitourinary dose 
that might be anticipated with intermittent motion. A recent analysis of patients undergoing 
SpaceOAR found 43% of patients with Grade ≥1 gastrointestinal toxicity with SpaceOAR vs. 51% 
without [23]. In this context the Grade 1 GI toxicity in the current study of 7% compares favorably. In 
this study 39% of patients were enrolled in a concurrent Phase I virtual high dose rate brachytherapy 
study, which delivered 2 large doses (>12Gy) followed by a planned 46Gy in 23 fractions. Patients 
from this study accounted for the two patients who required short term urinary catheterization. Both 
of these patients at last follow up were passing urine normally. Overall there does not appear to be an 
obvious increase (or decrease) in rectal or urinary toxicity due to the Calypso beacon placement or 
real time tracking. 
 
Additional factors of interest, not included in the trial design, are treatment times and MLC motor 
replacements.  The treatment times were not increased with electromagnetically-guided MLC 
tracking. The SBRT treatment sessions were completed within 30 minutes and the conventional 
fractionation treatment sessions within 15 minutes. There was no increase in MLC motor 
replacements.  Regarding an efficiency comparison with gating, Lovelock et al. [14] measured 1.7 
couch corrections per SBRT fraction using a 2 mm gating threshold. Thus the efficiency gain from 
MLC tracking over gating per fraction is approximately 1.7 times the entire beam off to beam on time 
for the couch correction.  
 
Though the prostate does not often move sufficiently to cause dosimetric deleterious effects, when it 
does, the use of MLC tracking means that the planned and delivered doses are much closer to each 
other than could be the case without MLC tracking. In this regard, MLC tracking is acting as a ‘safety 
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belt’, in which it is not needed most of the time, but is beneficial on the occasions it is needed.  Also 
of note is when the prostate moves anteriorly, without MLC tracking the rectal dose would be higher 
as it moves into the field, but the bladder dose reduced as it moves further from the field. These dose 
variations are reversed for posterior prostate motion. The clinical difference for prostate cancer will be 
found if these daily dose variations are important, or if MLC tracking enables margin reduction. When 
MLC tracking is applied to other organs in the body where motion is higher, particularly in the 
abdomen and thorax, the clinical benefits may also prove to be higher.   
 
This study had several limitations in addition to those common with marker-based prostate IGRT, 
such as contouring variations and the use of markers as surrogates. MLC tracking is limited by the 
finite leaf velocity and leaf width which limit the ability to correct for motion [24].  Target rotation, 
which can cause deleterious dosimetric effects for prostate radiotherapy, was ignored [25]. In 
principle target rotation can be corrected via MLC tracking [26], however as translational tracking is 
an emerging technology the clinical application of MLC tracking to account for target rotation is 
likely some years away.  Target deformation was also not accounted for. Where primary and nodal 
target treatments are involved, this represents a two-target system for MLC tracking in which the 
targets are unlikely to be moving synchronously.  Again, in principle, MLC tracking can account for 
target deformation [27], though the clinical timeline of this technology is uncertain.   
 
Conclusions 
Electromagnetic-guided MLC tracking radiotherapy for prostate cancer was proven to be feasible. The 
patients received improved geometric targeting and delivered dose distributions that were closer to 
those planned than they would have received without electromagnetic-guided MLC tracking. No acute 
grade ≥3 toxicity was observed. 
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Figure Captions 
 
Figure 1.  Schema for testing the primary and secondary outcomes. 
 
 
Figure 2.  (Top) The motion traces from the fractions that showed the largest geometric error with 
tracking (left) and estimated without tracking (right). Both the motion in the patient coordinate 
reference frame and the motion in the beam coordinate frame are shown. (Bottom) Summary statistics 
over all patients analyzed showing the magnitude of the beam-target geometric alignment with and 
without tracking parallel and perpendicular to the multileaf collimator (MLC) leaf travel direction.  
 
 
Figure 3.  The planned and delivered isodose plots for the treatment fractions that showed the largest 
beam-target geometric alignment error with tracking (left) and estimated without multileaf collimator 
tracking (right). The left and posterior motion, shown in Figure 2, results in the no tracking dose 
distribution being shifted relative to that planned, underdosing the clinical target volume (CTV) which 
is outlined on each figure. The isodose range is from 95-115%.  
 
 
Figure 4.  Improvement in dosimetric coverage of prostate and critical structures across the study. 
Shown are the calculated percentage dose difference from the planned value for the treated with MLC 
tracking (blue) and estimated without multileaf collimator tracking (red) dose distributions for (top) 
clinical target volume (CTV) D95% values (n=787 fractions) and the gross tumor volume (GTV) 
D95% values (n=490 fractions), and (bottom) rectum and bladder V50% values. The box limits 
represent the median and 25th and 75th percentiles. The whisker extents indicate the maximum and 
minimum values.  
 
 
Figure 5.  The acute genito-urinary (GU) and gastro-intestinal (GI) grade from the start of treatment, 
3 months and 12 months. The number of patients with a grade 1 or 2 toxicity (out of 28) at each time 
point is given in green. mRTOG = modified Radiation Therapy Oncology Group.  
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Table 1. Patient characteristics. 
Characteristic Value(s) Percentage 
Age (years)    
 Median 69 - 
 Range 57-83 - 
Pretreatment PSA 
(ng/mL) 
 
  
 <10 13 46% 
 10-20 12 43% 
 >20 3 11% 
Total Gleason score    
 6-7 13 46% 
 8-10 15 54% 
T and N stage    
 T1-T3 N0 26 93% 
 N1 2 7% 
Prostate volume (cc)    
 Median 50 - 
 Range 20-102 - 
Hydrogel spacer used?    
 Yes 20 71% 
 No 8 29% 
Prescribed Fractionation    
• Conventional* 2 Gy × 40 Fx; 11 of 14 with additional GTV 
escalation 14 50% 
• BOOSTER trial 
(NCT02004223)** 
12.5 or 13.75 Gy × 2 Fx (SBRT) + 2 Gy × 23 Fx 
(conventional); 9/11 with additional GTV 
escalation for the SBRT fractions, for three of these 
patients escalation continued for the 2 Gy fractions 
11 39% 
• HEAT trial SBRT arm 
(NCT01794403) 
7.25 Gy × 5 Fx; all with additional GTV escalation 2 7% 
• HEAT trial standard 
arm (NCT01794403) 
2.7 Gy × 26 Fx; with additional GTV escalation 1 4% 
*One patient required surgery for a newly diagnosed abdominal Desmoid tumor and his 
prescription was reduced with SBRT to 24 fractions in total 
** Two patients had the total fractionation changed on protocol due to i) newly diagnosed oral 
cancer and ii) urinary side effects requiring temporary catheterization.  
Fx = fraction; GTV = gross tumor volume; SBRT = stereotactic body radiotherapy 
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Summary 
 
The feasibility of electromagnetic-guided multileaf collimator (MLC) tracking radiotherapy was 
investigated in a prospective clinical trial. Twenty-eight men with prostate cancer were treated with 
technology where the tumor position was detected in real-time and the radiation beam adapted to target 
the tumor as it moved. All 858 attempted fractions were successfully delivered. MLC tracking improved 
the beam-target geometric alignment. MLC tracking improved the prostate dose coverage.  No acute 
grade ≥3 toxicity was observed.  
 
